Reply  by Herrmann, Joerg et al.
V
8
I
E
R
1
2
3
R
W
r
p
a
p
a
i
d
fi
r
a
t
p
a
t
V
t
p
w
c
i
e
l
s
s
s
c
a
d
N
p
i
s
e
d
y
t
s
t
p
e
i
*
S
L
A
*
M
2
R
E
R
1
2
3
1351JACC Vol. 52, No. 16, 2008 Correspondence
October 14, 2008:1347–51ia Costantinopoli 16
0138 Naples
taly
-mail: michele.damico@unina2.it
doi:10.1016/j.jacc.2008.06.045
EFERENCES
. Herrmann J, Soares SM, Lerman LO, Lerman A. Potential role of the
ubiquitin-proteasome system in atherosclerosis: aspects of a protein
quality disease. J Am Coll Cardiol 2008;51:2003–10.
. Marfella R, D’Amico M, Di Filippo C, et al. Increased activity of the
ubiquitin-proteasome system in patients with symptomatic carotid
disease is associated with enhanced inflammation and may destabilize
the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll
Cardiol 2006;47:2444–55.
. Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome
inhibition: new strategies in stroke therapy. Stroke 2004;35:1506–18.
eply
e thank Dr. Di Filippo and colleagues for their comment on our
ecent article (1) that a loss of the function of the ubiquitin-
roteasome system may present only one aspect of its role in the
therosclerotic disease process. They outline that the ubiquitin-
roteasome system serves a compensatory role to prevent the
ggregation of low-quality proteins in the vascular wall in the
nitial disease stage. This function is lost in the more advanced
isease stages as the ubiquitin-proteasome system becomes insuf-
cient to degrade the excess amounts of damaged proteins,
educing cell and tissue viability and fostering progression of
therosclerosis. Then again, inflammation, which has been so
ightly linked to atherosclerosis, may activate the ubiquitin-
roteasome system, which in turn can increase inflammatory
ctivity through synthesis of nuclear factor kappa B (NFkB) and
he generation of substrates for the ubiquitin-proteasome system.
ia this positive feedback cycle, the ubiquitin-proteasome system
akes a more active, contributing role to the atherosclerotic disease
rocess.
The presented viewpoint of their letter is in fact well aligned
ith the conceptual theme of our article. In support of a possible
ompensatory role of the ubiquitin-proteasome system in the
nitial stage of atherosclerosis, we described pro-atherosclerotic
ffects of chronic proteasome inhibition in experimental hypercho-
esterolemia (2). Further confirmation should be given by futuretudies showing a vasoprotective effect of the stimulation of the
ystem. Also, there is a need for studies on the modulation of the
ystem in the more advanced disease stages to truly confirm its
ausal role. In this, we are in full agreement with Dr. Di Filippo
nd colleagues.
Regarding inflammation, the ubiquitin-proteasome system in-
eed takes center stage in the classical activation pathway of
FkB, and its inhibition is thought to contribute to the efficacy of
roteasome inhibitors in chemotherapy. However, proteasome-
ndependent NFkB activation can still occur through the nonclas-
ical activation pathways that are stimulated under conditions of
nhanced oxidative stress (3). This reconciles the possible contra-
iction of an insufficiency of the ubiquitin-proteasome system and
et increased NFkB activation in advanced atherosclerosis. Cer-
ainly, an unimpaired and even stimulated ubiquitin-proteasome
ystem can contribute further to NFkB activation and inflamma-
ion in the initial stage of atherosclerosis as we outlined. Thus, the
oints made by Dr. Dr Filippo and colleagues are well taken and
mphasize the nuances of the topic and the need for further studies
n this area.
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